The Northern California Chapter of ISCEBS is pleased to share this
announcement for the Capital Chapter's June Webinar.
Ever since the human genetic code was first cracked in 2003, a revolution in the biotechnology sector was spurred in advancing gene-based medical and prescription drug testing and treatment to help people reduce the risk of disease to which they are genetically susceptible and increase the likelihood of drug treatment effectiveness influenced by an individual’s genetic make-up.
Advances in medical science and genomics have contributed to the fast-paced evolution of precision medicine, which is an “emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”1 Genetic testing and gene-based treatment are exciting DNA-based technologies that can help people live healthier lives. Sixteen years later, these technologies and treatment advancements are rapidly outpacing insurance companies’ and plan sponsors’ adoption of covering this new paradigm of precision medicine. With gene-based testing and therapy increasingly playing a key role in medical treatment, payers of care, including plan sponsors and insurance companies, along with patient management vendors and employees themselves, need to understand how to navigate in this new world.
Please join the Capital Chapter ISCEBS for a panel discussion on this engaging and timely topic and how to incorporate precision medicine into your benefit plans in a strategic, gainful manner with Joe Spinelli, the Chief Commercial Officer at Medtek21 in West Chester, PA and Dave Ratcliffe, Health & Productivity Practice Leader for the Washington, DC office of Buck and Dr. Shanna Ndong, MD, Medical Director, Cigna.
June 20, 2019 (Thursday)
8:45 - 10:15 am
$10 – Northern California
$25 – Nonmembers
Please click here to register.
(Webinar instructions will be emailed. If you have not received webinar instructions by June 18th, please contact Donna Malliett at:
so the instruction can be resent.)
This program qualifies for 1.5 CEBS Compliance credits.
Visit www.cebs.org/compliance for more information